On December 7, 2017 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that it will webcast its Analyst Day on Wednesday, December 13, 2017 from 9:00 a.m. to 12:00 p.m. ET in New York, NY (Press release, Iovance Biotherapeutics, DEC 7, 2017, View Source;p=RssLanding&cat=news&id=2321615 [SID1234522427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will highlight Iovance’s lead clinical programs, LN-144 for the treatment of metastatic melanoma, LN-145 for recurrent and/or metastatic squamous cell carcinoma of the head and neck, and LN-145 for recurrent, metastatic or persistent cervical cancer. In addition, Iovance will discuss the expanding clinical pipeline, strategic collaborations and manufacturing plan for upcoming clinical trials.

A live webcast of the presentation can be accessed on the investor page of Iovance Biotherapeutics’ website at View Source A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.